LOGIN  |  REGISTER
Assertio
Chimerix

Veeva Systems Announces Fiscal 2023 Third Quarter Results

December 01, 2022 | Last Trade: US$210.63 0.74 0.35
  • Total Revenues of $552.4M, up 16% Year Over Year; Subscription Services Revenues of $441.6M, up 16% Year Over Year

PLEASANTON, Calif., Dec. 1, 2022 /PRNewswire/ -- Veeva Systems Inc. (NYSE: VEEV), a leading provider of industry cloud solutions for the global life sciences industry, today announced results for its third quarter ended October 31, 2022.

"Consistent execution and strong innovation have us tracking a year ahead of our 2025 targets and set up for significant growth toward 2030 and beyond," said CEO Peter Gassner. "Thanks to the team's focus on customer success and product excellence, our impact and strategic partnership with the industry is increasing."

Fiscal 2023 Third Quarter Results:

  • Revenues: Total revenues for the third quarter were $552.4 million, up from $476.1 million one year ago, an increase of 16% year over year. Subscription services revenues for the third quarter were $441.6 million, up from $380.7 million one year ago, an increase of 16% year over year.

  • Operating Income and Non-GAAP Operating Income(1): Third quarter operating income was $121.4 million, compared to $132.7 million one year ago, a decrease of 9% year over year. Non-GAAP operating income for the third quarter was $219.5 million, compared to $199.4 million one year ago, an increase of 10% year over year.

  • Net Income and Non-GAAP Net Income(1): Third quarter net income was $108.5 million, compared to $105.9 million one year ago, an increase of 2% year over year. Non-GAAP net income for the third quarter was $183.2 million, compared to $158.2 million one year ago, an increase of 16% year over year.

  • Net Income per Share and Non-GAAP Net Income per Share(1): For the third quarter, fully diluted net income per share was $0.67, compared to $0.65 one year ago, while non-GAAP fully diluted net income per share was $1.13, compared to $0.97 one year ago.

"In the third quarter, we delivered strong financial performance across the board including results above our guidance," said CFO Brent Bowman. "We are well positioned for durable and profitable growth as we execute on the large opportunities in commercial and R&D."

Recent Highlights:

  • Groundbreaking Strategic Partnership — Veeva established a 10-year strategic partnership agreement with Merck, known as MSD outside of the United States and Canada, which builds on an existing 12-year partnership. Merck will take a Veeva-first approach to new industry-specific software and data, selecting Veeva products when they are fit for purpose. The partnership helps accelerate Merck's digital strategy and makes it more efficient to evaluate, purchase, operate, and create value from Veeva products. This agreement is the first of its kind for Veeva, supporting its vision to become the most strategic partner to the life sciences industry.

  • Expanding Clinical Leadership — The Veeva Vault Platform is delivering a unified suite of products that help customers manage their clinical operations more efficiently and speed drug development. These products are becoming the preferred choice among life sciences companies with more than 450 customers using Veeva Vault eTMF and more than 175 customers using Veeva Vault CTMS.

  • Veeva Vault Safety Reaches Critical Milestone — The first top 20 pharma customer went live with Vault Safety across their main divisions and most countries. Drug safety and pharmacovigilance is one of the most complex and critical areas for pharmaceutical companies. The successful go-live demonstrates Vault Safety's product readiness for the enterprise and Veeva's commitment to customer success and product excellence.

Financial Outlook:

Veeva is providing guidance for its fiscal fourth quarter ending January 31, 2023 as follows:

  • Total revenues between $551 and $553 million.

  • Non-GAAP operating income of about $199 million(2).

  • Non-GAAP fully diluted net income per share of approximately $1.05(2).

Veeva is providing updated guidance for its fiscal year ending January 31, 2023 as follows:

  • Total revenues between $2,143 and $2,145 million.

  • Non-GAAP operating income of about $820 million(2).

  • Non-GAAP fully diluted net income per share of approximately $4.19(2).

Conference Call Information

Prepared remarks and an investor presentation providing additional information and analysis can be found on Veeva's investor relations website at ir.veeva.com. Veeva will host a Q&A conference call at 2:00 p.m. PT today, December 1, 2022, and a replay of the call will be available on Veeva's investor relations website.

What:

Veeva Systems Fiscal 2023 Third Quarter Results Conference Call

When:

Thursday, December 1, 2022

Time:

2:00 p.m. PT (5:00 p.m. ET)

Online Registration:

https://conferencingportals.com/event/badXudFz

Webcast:

ir.veeva.com

___________

(1) This press release uses non-GAAP financial metrics that are adjusted for the impact of various GAAP items. See the section titled "Non-GAAP Financial Measures" and the tables entitled "Reconciliation of GAAP to Non-GAAP Financial Measures" below for details.

 

(2) Veeva is not able, at this time, to provide GAAP targets for operating income and fully diluted net income per share for the fourth fiscal quarter ending January 31, 2023 or fiscal year ending January 31, 2023 because of the difficulty of estimating certain items excluded from non-GAAP operating income and non-GAAP fully diluted net income per share that cannot be reasonably predicted, such as charges related to stock-based compensation expense and employer payroll taxes on CEO stock transactions. The effect of these excluded items may be significant.

About Veeva Systems

Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders and the industries it serves. For more information, visit veeva.com.

Veeva uses its ir.veeva.com website as a means of disclosing material non-public information, announcing upcoming investor conferences, and for complying with its disclosure obligations under Regulation FD. Accordingly, you should monitor our investor relations website in addition to following our press releases, SEC filings, and public conference calls and webcasts.

Forward-looking Statements

This release contains forward-looking statements regarding Veeva's expected future performance and, in particular, includes quotes from management and guidance provided as of December 1, 2022 about Veeva's expected future financial results. Estimating guidance accurately for future periods is difficult. It involves assumptions and internal estimates that may prove to be incorrect and is based on plans that may change. Hence, there is a significant risk that actual results could differ materially from the guidance we have provided in this release and we have no obligation to update such guidance. There are also numerous risks that have the potential to negatively impact our financial performance, including as a result of competitive factors, customer decisions and priorities, events that impact the life sciences industry, issues related to the security or performance of our products, issues that impact our ability to hire, retain and adequately compensate talented employees, the pandemic, fluctuations in foreign currency exchange rates, and general macroeconomic and geopolitical events (including inflationary pressures and impacts related to Russia's invasion of Ukraine). We have summarized what we believe are the principal risks to our business in a section titled "Summary of Risk Factors" on pages 39 and 40 in our filing on Form 10-Q for the period ended July 31, 2022 which you can find here. Additional details on the risks and uncertainties that may impact our business can be found in the same filing on Form 10-Q and in our subsequent SEC filings, which you can access at sec.gov. We recommend that you familiarize yourself with these risks and uncertainties before making an investment decision.

Investor Relations Contact:
Ato Garrett
Veeva Systems Inc.
925-271-4204
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact:
Maria Scurry
Veeva Systems Inc.
781-366-7617
This email address is being protected from spambots. You need JavaScript enabled to view it.

VEEVA SYSTEMS INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands)

(Unaudited)

 
 

October 31,
2022

 

January 31,
2022

Assets

   

Current assets:

   

Cash and cash equivalents

$         865,159

 

$      1,138,040

Short-term investments

2,157,396

 

1,238,064

Accounts receivable, net

242,859

 

631,134

Unbilled accounts receivable

82,085

 

63,266

Prepaid expenses and other current assets

38,986

 

36,679

Total current assets

3,386,485

 

3,107,183

Property and equipment, net

51,135

 

54,495

Deferred costs, net

27,875

 

33,106

Lease right-of-use assets

57,249

 

49,640

Goodwill

439,877

 

439,877

Intangible assets, net

87,382

 

101,940

Deferred income taxes

98,573

 

5,097

Other long-term assets

34,141

 

25,127

Total assets

$      4,182,717

 

$      3,816,465

    

Liabilities and stockholders' equity

   

Current liabilities:

   

Accounts payable

$           40,926

 

$           20,348

Accrued compensation and benefits

40,265

 

33,834

Accrued expenses and other current liabilities

32,860

 

36,109

Income tax payable

54,466

 

7,761

Deferred revenue

510,098

 

731,746

Lease liabilities

11,665

 

10,981

Total current liabilities

690,280

 

840,779

Deferred income taxes

1,546

 

2,216

Lease liabilities, noncurrent

50,225

 

43,607

Other long-term liabilities

21,874

 

18,226

Total liabilities

763,925

 

904,828

Stockholders' equity:

   

Class A common stock

2

 

2

Class B common stock

 

Additional paid-in capital

1,438,213

 

1,196,547

Accumulated other comprehensive loss

(45,642)

 

(11,958)

Retained earnings

2,026,219

 

1,727,046

Total stockholders' equity

3,418,792

 

2,911,637

Total liabilities and stockholders' equity

$      4,182,717

 

$      3,816,465

VEEVA SYSTEMS INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(In thousands, except per share data)

(Unaudited)

 
 

Three months ended
October 31,

 

Nine months ended
October 31,

 

2022

 

2021

 

2022

 

2021

Revenues:

       

Subscription services(3)

$ 441,569

 

$ 380,738

 

$  1,272,850

 

$  1,088,293

Professional services and other(4)

110,782

 

95,373

 

318,821

 

276,985

Total revenues

552,351

 

476,111

 

1,591,671

 

1,365,278

Cost of revenues(5):

       

Cost of subscription services

65,734

 

59,648

 

188,722

 

164,774

Cost of professional services and other

88,173

 

69,916

 

256,369

 

203,023

Total cost of revenues

153,907

 

129,564

 

445,091

 

367,797

Gross profit

398,444

 

346,547

 

1,146,580

 

997,481

Operating expenses(5):

       

Research and development

130,257

 

98,635

 

377,740

 

276,760

Sales and marketing

93,910

 

72,423

 

259,642

 

208,822

General and administrative

52,873

 

42,781

 

159,030

 

126,121

Total operating expenses

277,040

 

213,839

 

796,412

 

611,703

Operating income

121,404

 

132,708

 

350,168

 

385,778

Other income, net

12,458

 

824

 

23,565

 

7,054

Income before income taxes

133,862

 

133,532

 

373,733

 

392,832

Provision for income taxes

25,405

 

27,663

 

74,560

 

62,538

Net income

$ 108,457

 

$ 105,869

 

$ 299,173

 

$  330,294

Net income per share:

       

Basic

$       0.70

 

$       0.69

 

$       1.93

 

$       2.16

Diluted

$       0.67

 

$       0.65

 

$       1.84

 

$       2.03

Weighted-average shares used to compute net income per share:

       

Basic

155,392

 

153,514

 

154,958

 

153,020

Diluted

162,295

 

163,034

 

162,189

 

162,663

Other comprehensive income:

       

Net change in unrealized loss on available-for-sale investments

$  (17,499)

 

$    (2,741)

 

$  (30,722)

 

$    (4,044)

Net change in cumulative foreign currency translation loss

(808)

 

(308)

 

(2,962)

 

(2,686)

Comprehensive income

$   90,150

 

$ 102,820

 

$ 265,489

 

$  323,564

        

(3) Includes subscription services revenues from the following product areas:

       

Veeva Commercial Solutions

$ 239,276

 

$ 223,183

 

$ 703,356

 

$  649,156

Veeva R&D Solutions

202,293

 

157,555

 

569,494

 

439,137

Total subscription services

$ 441,569

 

$ 380,738

 

$  1,272,850

 

$  1,088,293

        

(4) Includes professional services and other revenues from the following product areas:

       

Veeva Commercial Solutions

$   45,283

 

$   41,675

 

$ 133,027

 

$  124,241

Veeva R&D Solutions

65,499

 

53,698

 

185,794

 

152,744

Total professional services and other

$ 110,782

 

$   95,373

 

$ 318,821

 

$  276,985

        

(5) Includes stock-based compensation as follows:

       

Cost of revenues:

       

Cost of subscription services

1,636

 

1,292

 

$     4,606

 

3,514

Cost of professional services and other

13,227

 

9,616

 

$   37,035

 

26,579

Research and development

37,415

 

22,311

 

102,139

 

61,463

Sales and marketing

23,576

 

15,102

 

64,500

 

41,772

General and administrative

17,333

 

13,724

 

48,083

 

39,591

Total stock-based compensation

$   93,187

 

$   62,045

 

$ 256,363

 

$  172,919

VEEVA SYSTEMS INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

 
 

Three months ended
October 31,

 

Nine months ended
October 31,

 

2022

 

2021

 

2022

 

2021

Cash flows from operating activities

       

Net income

$     108,457

 

$     105,869

 

$     299,173

 

$     330,294

Adjustments to reconcile net income to net cash provided by operating activities:

       

Depreciation and amortization

7,157

 

6,899

 

21,443

 

20,407

Reduction of operating lease right-of-use assets

3,094

 

2,855

 

9,062

 

8,556

(Accretion) amortization of discount on short-term investments

(1,565)

 

1,574

 

(1,016)

 

4,859

Stock-based compensation

93,187

 

62,045

 

256,363

 

172,919

Amortization of deferred costs

5,378

 

6,597

 

17,107

 

19,426

Deferred income taxes

(31,056)

 

(2,021)

 

(84,369)

 

10,174

 Loss (gain) on foreign currency from mark-to-market derivative

7

 

(65)

 

1,193

 

368

Bad debt expense

1,089

 

58

 

1,210

 

195

Changes in operating assets and liabilities:

       

Accounts receivable

69,272

 

72,147

 

387,066

 

352,470

Unbilled accounts receivable

(4,307)

 

(16,870)

 

(18,819)

 

(20,764)

Deferred costs

(5,376)

 

(3,353)

 

(11,876)

 

(11,445)

Other current and long-term assets

7,326

 

4,407

 

(3,750)

 

3,278

Accounts payable

10,002

 

4,028

 

20,663

 

2,265

Accrued expenses and other current liabilities

5,465

 

(537)

 

2,654

 

8,646

Income taxes payable

49,323

 

12,010

 

46,705

 

11,993

Deferred revenue

(174,544)

 

(141,083)

 

(222,013)

 

(199,042)

Operating lease liabilities

(2,624)

 

(2,941)

 

(7,736)

 

(8,602)

Other long-term liabilities

2,375

 

1,340

 

4,013

 

4,412

Net cash provided by operating activities

142,660

 

112,959

 

717,073

 

710,409

Cash flows from investing activities

       

Purchases of short-term investments

(710,833)

 

(256,008)

 

(1,716,250)

 

(935,626)

Maturities and sales of short-term investments

310,713

 

248,093

 

757,434

 

657,062

Acquisitions, net of cash and restricted cash acquired

 

 

 

(2,133)

Long-term assets

(5,609)

 

(2,314)

 

(9,605)

 

(10,295)

Net cash used in investing activities

(405,729)

 

(10,229)

 

(968,421)

 

(290,992)

Cash flows from financing activities

       

Changes in lease liabilities - finance leases

 

 

 

(384)

Proceeds from exercise of common stock options

4,575

 

5,368

 

30,116

 

43,310

Taxes paid related to net share settlement of equity awards

(15,118)

 

(21,414)

 

(47,251)

 

(36,510)

Net cash (used in) provided by financing activities

(10,543)

 

(16,046)

 

(17,135)

 

6,416

Effect of exchange rate changes on cash, cash equivalents, and restricted cash

(1,475)

 

(1,469)

 

(4,398)

 

(4,414)

Net change in cash, cash equivalents, and restricted cash

(275,087)

 

85,215

 

(272,881)

 

421,419

Cash, cash equivalents, and restricted cash at beginning of period

1,143,431

 

1,067,916

 

1,141,225

 

731,712

Cash, cash equivalents, and restricted cash at end of period

$     868,344

 

$  1,153,131

 

$     868,344

 

$  1,153,131

        

Supplemental disclosures of other cash flow information:

       

Excess tax benefits from employee stock plans

$            888

 

$       10,404

 

$         5,981

 

$       45,464

Non-GAAP Financial Measures
In Veeva's public disclosures, Veeva has provided non-GAAP measures, which it defines as financial information that has not been prepared in accordance with generally accepted accounting principles in the United States, or GAAP. In addition to its GAAP measures, Veeva uses these non-GAAP financial measures internally for budgeting and resource allocation purposes and in analyzing its financial results. For the reasons set forth below, Veeva believes that excluding the following items provides information that is helpful in understanding its operating results, evaluating its future prospects, comparing its financial results across accounting periods, and comparing its financial results to its peers, many of which provide similar non-GAAP financial measures.

  • Excess tax benefits. Excess tax benefits from employee stock plans are dependent on previously agreed-upon equity grants to our employees, vesting of those grants, stock price, and exercise behavior of our employees, which can fluctuate from quarter to quarter. Because these fluctuations are not directly related to our business operations, Veeva excludes excess tax benefits for its internal management reporting processes. Veeva management also finds it useful to exclude excess tax benefits when assessing the level of cash provided by operating activities. Given the nature of the excess tax benefits, Veeva believes excluding it allows investors to make meaningful comparisons between our operating cash flows from quarter to quarter and those of other companies.

  • Impact of tax legislation. Veeva excludes the direct cash payments associated with the newly effective tax legislation requiring the capitalization of certain research and development expenses for purposes of calculating non-GAAP operating cash flows. Veeva does not believe the impact resulting from changes in the tax treatment of research and development costs to be indicative of its operating performance, nor does Veeva management consider such impact in assessing the level of cash provided by operating activities. Accordingly, Veeva believes excluding the impact of this change in tax law provides for better evaluation of its current operating performance and comparison to past operating results.

  • Stock-based compensation expenses. Veeva excludes stock-based compensation expenses primarily because they are non-cash expenses that Veeva excludes from its internal management reporting processes. Veeva's management also finds it useful to exclude these expenses when they assess the appropriate level of various operating expenses and resource allocations when budgeting, planning and forecasting future periods. Moreover, because of varying available valuation methodologies, subjective assumptions and the variety of award types that companies can use, Veeva believes excluding stock-based compensation expenses allows investors to make meaningful comparisons between our recurring core business operating results and those of other companies.

  • Amortization of purchased intangibles. Veeva incurs amortization expense for purchased intangible assets in connection with acquisitions of certain businesses and technologies. Amortization of intangible assets is a non-cash expense and is inconsistent in amount and frequency because it is significantly affected by the timing, size of acquisitions and the inherent subjective nature of purchase price allocations. Because these costs have already been incurred and cannot be recovered, and are non-cash expenses, Veeva excludes these expenses for its internal management reporting processes. Veeva's management also finds it useful to exclude these charges when assessing the appropriate level of various operating expenses and resource allocations when budgeting, planning and forecasting future periods. Investors should note that the use of intangible assets contributed to Veeva's revenues earned during the periods presented and will contribute to Veeva's future period revenues as well.

  • Income tax effects on the difference between GAAP and non-GAAP costs and expenses. The income tax effects that are excluded relate to the imputed tax impact on the difference between GAAP and non-GAAP costs and expenses due to stock-based compensation and purchased intangibles for GAAP and non-GAAP measures.

There are limitations to using non-GAAP financial measures because non-GAAP financial measures are not prepared in accordance with GAAP and may be different from non-GAAP financial measures provided by other companies. The non-GAAP financial measures are limited in value because they exclude certain items that may have a material impact upon our reported financial results. In addition, they are subject to inherent limitations as they reflect the exercise of judgments by Veeva's management about which items are adjusted to calculate its non-GAAP financial measures. Veeva compensates for these limitations by analyzing current and future results on a GAAP basis as well as a non-GAAP basis and also by providing GAAP measures in its public disclosures.

Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Veeva encourages its investors and others to review its financial information in its entirety, not to rely on any single financial measure to evaluate its business, and to view its non-GAAP financial measures in conjunction with the most directly comparable GAAP financial measures. A reconciliation of GAAP to the non-GAAP financial measures has been provided in the tables below.

VEEVA SYSTEMS INC. 

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES 

(Dollars in thousands) 

(Unaudited) 

 

The following tables reconcile the specific items excluded from GAAP metrics in the calculation of non-GAAP metrics for the periods shown below: 

 

Reconciliation of Net Cash Provided by Operating Activities (GAAP basis to non-GAAP basis)

Three months ended
October 31,

 

Nine months ended
October 31,

 
 

2022

 

2021

 

2022

 

2021

 

Net cash provided by operating activities

$                 142,660

 

$  112,959

 

$                   717,073

 

$                   710,409

 

Excess tax benefits from employee stock plans

(888)

 

(10,404)

 

(5,981)

 

(45,464)

 

Impact of tax legislation

 

 

37,946

 

 

Net cash provided by operating activities on a non-GAAP basis

$                 141,772

 

$  102,555

 

$                   749,038

 

$                   664,945

 

Net cash used in investing activities

$                (405,729)

 

$   (10,229)

 

$                  (968,421)

 

$                  (290,992)

 

Net cash (used in) provided by financing activities

$                  (10,543)

 

$   (16,046)

 

$                    (17,135)

 

$                       6,416

 
         

Reconciliation of Financial Measures (GAAP basis to non-GAAP basis)

Three months ended
October 31,

 

Nine months ended
October 31,

 
 

2022

 

2021

 

2022

 

2021

 

Cost of subscription services revenues on a GAAP basis

$                  65,734

 

$    59,648

 

$                   188,722

 

$                 164,774

 

Stock-based compensation expense

(1,636)

 

(1,292)

 

(4,606)

 

(3,514)

 

Amortization of purchased intangibles

(1,126)

 

(1,005)

 

(3,342)

 

(2,826)

 

Cost of subscription services revenues on a non-GAAP basis

$                  62,972

 

$    57,351

 

$                   180,774

 

$                 158,434

 
         

Gross margin on subscription services revenues on a GAAP basis

85.1 %

 

84.3 %

 

85.2 %

 

84.9 %

 

Stock-based compensation expense

0.4

 

0.3

 

0.3

 

0.3

 

Amortization of purchased intangibles

0.2

 

0.3

 

0.3

 

0.3

 

Gross margin on subscription services revenues on a non-GAAP basis

85.7 %

 

84.9 %

 

85.8 %

 

85.5 %

 
         

Cost of professional services and other revenues on a GAAP basis

$                 88,173

 

$    69,916

 

$                  256,369

 

$                 203,023

 

Stock-based compensation expense

(13,227)

 

(9,616)

 

(37,035)

 

(26,579)

 

Amortization of purchased intangibles

(139)

 

(139)

 

(411)

 

(411)

 

Cost of professional services and other revenues on a non-GAAP basis

$                 74,807

 

$    60,161

 

$                  218,923

 

$                 176,033

 
         

Gross margin on professional services and other revenues on a GAAP basis

20.4 %

 

26.7 %

 

19.6 %

 

26.7 %

 

Stock-based compensation expense

11.9

 

10.1

 

11.6

 

9.6

 

Amortization of purchased intangibles

0.2

 

0.1

 

0.1

 

0.1

 

Gross margin on professional services and other revenues on a non-GAAP basis

32.5 %

 

36.9 %

 

31.3 %

 

36.4 %

 
         

Gross profit on a GAAP basis

$                 398,444

 

$  346,547

 

$               1,146,580

 

$                 997,481

 

Stock-based compensation expense

14,863

 

10,908

 

41,641

 

30,093

 

Amortization of purchased intangibles

1,265

 

1,144

 

3,754

 

3,237

 

Gross profit on a non-GAAP basis

$                 414,572

 

$  358,599

 

$               1,191,975

 

$              1,030,811

 
         

Gross margin on total revenues on a GAAP basis

72.1 %

 

72.8 %

 

72.0 %

 

73.1 %

 

Stock-based compensation expense

2.7

 

2.3

 

2.6

 

2.2

 

Amortization of purchased intangibles

0.3

 

0.2

 

0.3

 

0.2

 

Gross margin on total revenues on a non-GAAP basis

75.1 %

 

75.3 %

 

74.9 %

 

75.5 %

 
         

Research and development expense on a GAAP basis

$                 130,257

 

$    98,635

 

$                  377,740

 

$                 276,760

 

Stock-based compensation expense

(37,415)

 

(22,311)

 

(102,139)

 

(61,463)

 

Amortization of purchased intangibles

(29)

 

(29)

 

(85)

 

(85)

 

Research and development expense on a non-GAAP basis

$                   92,813

 

$    76,295

 

$                  275,516

 

$                215,212

 
         
         

VEEVA SYSTEMS INC.

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (continued)

(Dollars in thousands, except per share data)

(Unaudited)

 
 

Three months ended
October 31,

 

Nine months ended
October 31,

 
 

2022

 

2021

 

2022

 

2021

 
         

Sales and marketing expense on a GAAP basis

$                   93,910

 

$    72,423

 

$                 259,642

 

$                 208,822

 

Stock-based compensation expense

(23,576)

 

(15,102)

 

(64,500)

 

(41,772)

 

Amortization of purchased intangibles

(3,555)

 

(3,464)

 

(10,550)

 

(10,210)

 

Sales and marketing expense on a non-GAAP basis

$                   66,779

 

$    53,857

 

$                 184,592

 

$                 156,840

 
         

General and administrative expense on a GAAP basis

$                   52,873

 

$    42,781

 

$                 159,030

 

$                 126,121

 

Stock-based compensation expense

(17,333)

 

(13,724)

 

(48,083)

 

(39,591)

 

Amortization of purchased intangibles

(57)

 

(57)

 

(169)

 

(169)

 

General and administrative expense on a non-GAAP basis

$                   35,483

 

$    29,000

 

$                 110,778

 

$                   86,361

 
         

Operating expense on a GAAP basis

$                 277,040

 

$  213,839

 

$                 796,412

 

$                 611,703

 

Stock-based compensation expense

(78,324)

 

(51,137)

 

(214,722)

 

(142,826)

 

Amortization of purchased intangibles

(3,641)

 

(3,550)

 

(10,804)

 

(10,464)

 

Operating expense on a non-GAAP basis

$                 195,075

 

$  159,152

 

$                 570,886

 

$                 458,413

 
         

Operating income on a GAAP basis

$                 121,404

 

$  132,708

 

$                 350,168

 

$                 385,778

 

Stock-based compensation expense

93,187

 

62,045

 

256,363

 

172,919

 

Amortization of purchased intangibles

4,906

 

4,694

 

14,558

 

13,701

 

Operating income on a non-GAAP basis

$                 219,497

 

$  199,447

 

$                 621,089

 

$                 572,398

 
         

Operating margin on a GAAP basis

22.0 %

 

27.9 %

 

22.0 %

 

28.3 %

 

Stock-based compensation expense

16.9

 

13.0

 

16.1

 

12.7

 

Amortization of purchased intangibles

0.8

 

1.0

 

0.9

 

1.0

 

Operating margin on a non-GAAP basis

39.7 %

 

41.9 %

 

39.0 %

 

42.0 %

 
         

Net income on a GAAP basis

$                 108,457

 

$  105,869

 

$                 299,173

 

$                 330,294

 

Stock-based compensation expense

93,187

 

62,045

 

256,363

 

172,919

 

Amortization of purchased intangibles

4,906

 

4,694

 

14,558

 

13,701

 

Income tax effect on non-GAAP adjustments(6)

(23,306)

 

(14,394)

 

(60,817)

 

(59,147)

 

Net income on a non-GAAP basis

$                 183,244

 

$  158,214

 

$                 509,277

 

$                 457,767

 
         

Diluted net income per share on a GAAP basis

$                       0.67

 

$        0.65

 

$                       1.84

 

$                       2.03

 

Stock-based compensation expense

0.57

 

0.38

 

1.58

 

1.06

 

Amortization of purchased intangibles

0.03

 

0.03

 

0.09

 

0.08

 

Income tax effect on non-GAAP adjustments(6)

(0.14)

 

(0.09)

 

(0.37)

 

(0.36)

 

Diluted net income per share on a non-GAAP basis

$                      1.13

 

$       0.97

 

$                      3.14

 

$                       2.81

 

________________________

(6)

For the three and nine months October 31, 2022 and 2021, management used an estimated annual effective non-GAAP tax rate of 21.0%.

Viking Therapeutics

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB